Streetbeat News

Regulatory

MRNA

PFE

Vaccine-maker stocks, including Moderna and Pfizer, fell after President-elect Donald Trump announced Robert F. Kennedy Jr., a known vaccine skeptic, as his pick to lead the U.S. Department of Health and Human Services.

Portfolio Pulse from

November 14, 2024 | 10:00 pm

XGN

Exagen Inc. has completed validation and regulatory submission for new lupus and rheumatoid arthritis biomarkers on its AVISE® CTD platform, enhancing diagnostic clarity for autoimmune diseases.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

PGEN

Precigen, Inc. reported its Q3 2024 financial results and business updates, highlighting progress in its gene and cell therapy programs. The company completed a pre-BLA meeting with the FDA for PRGN-2012, initiated a confirmatory trial, and is preparing for a potential 2025 launch. Additionally, Precigen is preparing for an end of Phase 1b meeting for PRGN-3006 and presented promising preclinical data for PRGN-3008.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

CKPT

Checkpoint Therapeutics' cosibelimab shows promising results for cSCC treatment. The upcoming PDUFA date on December 28th is crucial for potential FDA approval, which could drive significant market growth despite competitive pressures.

Portfolio Pulse from

November 14, 2024 | 9:30 pm

PSTV

Plus Therapeutics reported its Q3 2024 financial results and highlighted significant business developments, including FDA approval for a Phase 1 trial of Rhenium (186 Re) Obisbemeda for leptomeningeal metastases, positive trial data presentation, and a manufacturing partnership with SpectronRx.

Portfolio Pulse from

November 14, 2024 | 9:30 pm

TSLA

Tesla shares fell after news that the Trump administration plans to remove EV tax credits. However, this was already priced into the stock, and there are reasons for investors to remain optimistic.

Portfolio Pulse from

November 14, 2024 | 9:30 pm

FBIO

Fortress Biotech announced its Q3 2024 financial results and highlighted recent corporate developments, including FDA approval of Emrosi for rosacea treatment and an upcoming PDUFA date for Cosibelimab.

Portfolio Pulse from

November 14, 2024 | 9:30 pm

MYGN

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Myriad Genetics, Inc. investors. The investigation follows UnitedHealth Group's decision to no longer cover certain Myriad services.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

AMGN

Amgen has stated that there is no connection between the administration of its obesity candidate, MariTide, and changes in bone mineral density. This addresses concerns that had been raised about potential side effects of the drug.

Portfolio Pulse from

November 14, 2024 | 9:15 pm